Sidoti Csr Predicts Kamada's Q2 Earnings (NASDAQ:KMDA)

Kamada Ltd. (NASDAQ:KMDA - Free Report) - Equities researchers at Sidoti Csr boosted their Q2 2025 earnings per share estimates for shares of Kamada in a research note issued to investors on Monday, March 3rd. Sidoti Csr analyst J. Sidoti now expects that the biotechnology company will post earnings of $0.08 per share for the quarter, up from their previous estimate of $0.07. The consensus estimate for Kamada's current full-year earnings is $0.23 per share. Sidoti Csr also issued estimates for Kamada's Q3 2025 earnings at $0.08 EPS.

Separately, HC Wainwright reiterated a "buy" rating and issued a $11.00 price objective on shares of Kamada in a report on Thursday.

Kamada Stock Up 1.2 %

Shares of NASDAQ:KMDA traded up $0.09 during trading on Tuesday, hitting $7.41. The stock had a trading volume of 266,599 shares, compared to its average volume of 264,311. Kamada has a 12 month low of $4.74 and a 12 month high of $9.15. The company has a market capitalization of $425.93 million, a PE ratio of 26.46, a PEG ratio of 0.97 and a beta of 0.99. The firm's fifty day moving average is $7.10 and its 200 day moving average is $6.15.

Kamada Dividend Announcement

The firm also recently announced a dividend, which will be paid on Monday, April 7th. Stockholders of record on Monday, March 17th will be issued a dividend of $0.20 per share. The ex-dividend date is Monday, March 17th.

Institutional Trading of Kamada

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. NewEdge Advisors LLC boosted its holdings in Kamada by 54.2% in the fourth quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock worth $143,000 after acquiring an additional 8,260 shares in the last quarter. Aristides Capital LLC raised its position in shares of Kamada by 12.1% in the 4th quarter. Aristides Capital LLC now owns 63,485 shares of the biotechnology company's stock worth $387,000 after purchasing an additional 6,850 shares during the last quarter. Geode Capital Management LLC boosted its stake in Kamada by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock worth $178,000 after purchasing an additional 1,549 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in Kamada during the 4th quarter valued at about $67,000. Finally, Public Employees Retirement System of Ohio purchased a new stake in Kamada during the 3rd quarter valued at about $77,000. Hedge funds and other institutional investors own 20.38% of the company's stock.

Remove Ads

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.